PHILADELPHIA, PA — Century Therapeutics Inc. (Nasdaq: IPSC) will meet with investors at the Jefferies Global Healthcare Conference in London on November 18, as the Philadelphia biotechnology company advances experimental stem cell-derived therapies for type 1 diabetes, other autoimmune diseases and cancer.
The company confirmed its participation in the conference, with opportunities for individual meetings between its management team and institutional investors.
Century is developing cell therapies derived from induced pluripotent stem cells, or iPSCs, which can be engineered to produce specialized therapeutic cells.
Its development strategy centers on manufacturing off-the-shelf treatments rather than producing individualized therapies for each patient, an approach intended to make cell-based treatments more broadly accessible.
The company’s technology includes its proprietary Allo-Evasion platform, which is designed to help engineered therapeutic cells avoid immune rejection.
Century is pursuing applications in autoimmune diseases, including type 1 diabetes, as well as oncology. Its therapies remain investigational.
Investors interested in scheduling one-on-one meetings with Century representatives during the November 18 conference should contact their respective Jefferies representatives.
The company’s participation provides an opportunity to discuss its development strategy and therapeutic pipeline with investors attending the international healthcare conference.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.